Recent dyslipidemia guidelines for patients with diabetes mellitus

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2020-09-09 DOI:10.23838/pfm.2020.00100
E. Rhee
{"title":"Recent dyslipidemia guidelines for patients with diabetes mellitus","authors":"E. Rhee","doi":"10.23838/pfm.2020.00100","DOIUrl":null,"url":null,"abstract":"Treatment of diabetic dyslipidemia is important for the prevention of cardiovascular diseases in patients with diabetes. Although glucose control is the main target in patients with diabetes mellitus (DM) to prevent diabetic complications, multifactorial interventions are absolutely important to reduce the risk of cardiovascular diseases. Recent joint guidelines from the European Society of Cardiology and European Society for the Study of Diabetes have recommended lower low-density lipoprotein cholesterol (LDL-C) targets for patients with DM and included DM duration in the stratification of risk groups for cardiovascular disease prevention, emphasizing higher cardiovascular risk in patients with DM. In addition, the American Heart Association/American College of Cardiology guidelines were revised so that the LDL-C cutoff appeared in the guidelines for high risk groups and for changes in treatment options. The Korean Diabetes Association also released new treatment guidelines for patients with DM and adopted recent changes from other guidelines with respect to dyslipidemia control. In this review, I examined recent updates in the guidelines for dyslipidemia treatment for patients with DM.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2020-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/pfm.2020.00100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Treatment of diabetic dyslipidemia is important for the prevention of cardiovascular diseases in patients with diabetes. Although glucose control is the main target in patients with diabetes mellitus (DM) to prevent diabetic complications, multifactorial interventions are absolutely important to reduce the risk of cardiovascular diseases. Recent joint guidelines from the European Society of Cardiology and European Society for the Study of Diabetes have recommended lower low-density lipoprotein cholesterol (LDL-C) targets for patients with DM and included DM duration in the stratification of risk groups for cardiovascular disease prevention, emphasizing higher cardiovascular risk in patients with DM. In addition, the American Heart Association/American College of Cardiology guidelines were revised so that the LDL-C cutoff appeared in the guidelines for high risk groups and for changes in treatment options. The Korean Diabetes Association also released new treatment guidelines for patients with DM and adopted recent changes from other guidelines with respect to dyslipidemia control. In this review, I examined recent updates in the guidelines for dyslipidemia treatment for patients with DM.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
近期糖尿病患者血脂异常指南
糖尿病血脂异常的治疗对于预防糖尿病患者的心血管疾病非常重要。尽管血糖控制是糖尿病(DM)患者预防糖尿病并发症的主要目标,但多因素干预对于降低心血管疾病的风险绝对重要。欧洲心脏病学会和欧洲糖尿病研究学会最近的联合指南建议糖尿病患者达到较低的低密度脂蛋白胆固醇(LDL-C)目标,并将糖尿病持续时间纳入心血管疾病预防的风险组分层,强调糖尿病患者的心血管风险较高。此外,修订了美国心脏协会/美国心脏病学会指南,使LDL-C临界值出现在高危人群和治疗方案变化的指南中。韩国糖尿病协会还发布了针对糖尿病患者的新治疗指南,并在控制血脂异常方面采用了与其他指南相比的最新变化。在这篇综述中,我研究了糖尿病患者血脂异常治疗指南的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1